Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical Development

Revelation Biosciences (NASDAQ:REVB) announced the initiation of GMP manufacturing for GEMINI and matching placebo to supply later‑stage clinical studies.

Rhea-AI Summary

Revelation Biosciences (NASDAQ:REVB) announced the initiation of GMP manufacturing for GEMINI and matching placebo to supply later‑stage clinical studies. The manufacturing run will provide clinical drug supply needed to support randomized, double‑blind, placebo‑controlled trials and is described as a critical step toward advancing GEMINI's development and approval pathway.

The company said it is working with a leading global contract manufacturing organization and noted it met with the FDA in December 2025 to seek agency feedback on the clinical development and regulatory pathway for GEMINI as a treatment for acute kidney injury (AKI); Revelation is awaiting the FDA meeting minutes.

Positive

• GMP manufacturing for GEMINI and placebo initiated
• Manufacture will provide clinical supply for later‑stage studies
• Enables randomized double‑blind, placebo‑controlled trials
• Engaged a "leading global" contract manufacturing organization
• Met with FDA in December 2025 to discuss regulatory pathway

Negative

• Official FDA meeting minutes pending, creating regulatory timing uncertainty

Argus Jan 7 session

-1.08% close to close Open Argus

Details

News Market Reaction – REVB

On Jan 7, the day this news came out, REVB closed 1.08% below the previous close.

Data tracked by StockTitan Argus for the Jan 7 session.

Historical Context

5 past events · Latest: Dec 01

5 events

1. Dec 01

   Special meeting quorum

   24h Move

   +0.1%

   Confirmed quorum and reiterated regulatory and financial progress, slight price uptick.

2. Nov 20

   Clinical/FDA update

   24h Move

   -0.5%

   End-of-phase 1 package accepted and positive PRIME data, but shares slipped modestly.

3. Nov 06

   Earnings and cash update

   24h Move

   -2.9%

   Q3 loss, going concern language, and financing reliance drove a multi‑percent decline.

4. Oct 29

   Meeting cancellation

   24h Move

   -4.5%

   Technical issues forced canceling a special meeting, prompting a sharper share pullback.

5. Oct 15

   Meeting adjournment

   24h Move

   -2.2%

   Adjourned special meeting for lack of votes, adding governance overhang and losses.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

gmp manufacturing, placebo-controlled, double blinded, acute kidney injury, +1 more

5 terms

gmp manufacturing technical

"announced the start of GMP manufacturing of GEMINI and placebo."

GMP manufacturing, or Good Manufacturing Practice, is a set of strict guidelines that ensure products, especially medicines and health-related items, are consistently produced and controlled to meet quality standards. For investors, it signifies that a company follows high-quality processes, reducing risks of defects or contamination, which can impact product safety and market trust. This adherence helps ensure the reliability and reputation of the products in the marketplace.

placebo-controlled medical

"conduct randomized double blinded, placebo-controlled clinical studies, and is"

"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.

double blinded medical

"conduct randomized double blinded, placebo-controlled clinical studies, and is"

A double-blinded study is a test in which neither the participants nor the people administering the treatment know who receives the active product and who receives a placebo. This setup reduces conscious and unconscious bias, much like hiding the team colors from both players and referees so calls stay fair. For investors, double-blinding improves confidence that reported results reflect the product’s true effect, affecting regulatory chances, perceived risk and valuation.

acute kidney injury medical

"for Gemini as a treatment for acute kidney injury (AKI)."

A sudden decline in how well the kidneys remove waste and balance fluids, often developing over hours or days; think of it like an engine that abruptly loses power and can’t filter efficiently. It matters to investors because it can drive higher medical costs, alter clinical trial results, trigger regulatory scrutiny, lead to drug label changes or recalls, and affect revenue and liability for healthcare and life sciences companies.

fda regulatory

"Revelation met with FDA in December 2025 and is currently awaiting"

The FDA is the U.S. federal agency that evaluates and approves medical drugs, devices, biological therapies and certain foods; think of it as the gatekeeper that decides whether a medical product is safe and effective for patients. For investors, FDA decisions determine whether a company can sell a product, affect expected revenue and introduce regulatory risk, so approvals, rejections or safety warnings can quickly move a company's valuation and stock price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, CA / ACCESS Newswire / January 7, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation, today announced the start of GMP manufacturing of GEMINI and placebo. This manufacturing run will provide the Company with clinical drug supply for later stage clinical studies.

"We are delighted to be working with a leading global contract manufacturing organization," said James Rolke, Chief Executive Officer of Revelation. "The manufacture of additional drug supply and placebo will fulfill a critical step in advancing Revelation's pipeline and accelerating timelines for upcoming clinical programs."

The manufacture of drug and Placebo enables the company to conduct randomized double blinded, placebo-controlled clinical studies, and is an integral part of the broader strategy to move Gemini toward approval.

Revelation met with FDA in December 2025 and is currently awaiting the official meeting minutes. The primary purpose of this meeting was to establish agency feedback and input into the clinical development and regulatory approval pathway for Gemini as a treatment for acute kidney injury (AKI).

About Gemini

Gemini is the Company's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD^®), a toll-like receptor 4 (TLR4) agonist. TLR4 stimulation with Gemini rebalances the innate immune response and has been demonstrated to have the potential to treat acute and chronic diseases associated with dysregulated inflammation. Gemini is currently being evaluated as a potential treatment for acute kidney injury (GEMINI-AKI program). Gemini is also being developed as a treatment for chronic kidney disease (GEMINI-CKD program), as a treatment to reduce hyperinflammation and infection associated with severe burn (GEM-PBI) and as a treatment to prevent post-surgical infection (GEMINI-PSI program). The potential of Gemini has been demonstrated in multiple preclinical models of AKI, CKD and infection, as well as in two phase 1 clinical studies. See additional detail here.

About AKI

Acute Kidney Injury or AKI, also known as acute renal failure, is defined as a rapid loss of kidney function. AKI causes a build-up of waste products in blood and makes it more difficult for kidneys to maintain the correct balance of fluid in the body. AKI can also significantly impact other organs such as the brain, heart, and lungs. Severe AKI requiring dialysis significantly increases the likelihood of worse outcomes including longer time in an ICU, potential to develop chronic kidney disease and death.

AKI is a major cause of morbidity and mortality, affecting more than 10% of all hospitalized patients and more than 50% of patients admitted to intensive care units. Renal replacement therapy (dialysis) is still the only therapeutic option in the treatment of the consequences of severe AKI and is required in approximately 20% of all critically ill patients. Despite the fact that these patients show high mortality rates, up to 40% of patients who survive such an episode develop chronic kidney disease or end-stage renal disease. As such, new therapies to treat AKI are currently needed.

About Revelation Biosciences, Inc.

Revelation Biosciences, Inc. is a clinical stage life sciences company focused on rebalancing inflammation using its proprietary formulation Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including the treatment of chronic kidney disease, prevention for post-surgical infection and as a treatment for acute kidney injury.

For more information on Revelation, please visit www.RevBiosciences.com.

Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the words "anticipate", "believe", "expect", "estimate", "plan", "outlook", and "project" and other similar expressions. We caution investors that forward-looking statements are based on management's expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements. Revelation cautions readers not to place undue reliance on any such forward looking statements, which speak only as of the date they were made. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability of Revelation to meet its financial and strategic goals, due to, among other things, competition; the ability of Revelation to grow and manage growth profitability and retain its key employees; the possibility that the Revelation may be adversely affected by other economic, business, and/or competitive factors; risks relating to the successful development of Revelation's product candidates; the ability to successfully complete planned clinical studies of its product candidates; the risk that we may not fully enroll our clinical studies or enrollment will take longer than expected; risks relating to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from our clinical studies; changes in applicable laws or regulations; expected initiation of the clinical studies, the timing of clinical data; the outcome of the clinical data, including whether the results of such study is positive or whether it can be replicated; the outcome of data collected, including whether the results of such data and/or correlation can be replicated; the timing, costs, conduct and outcome of our other clinical studies; the anticipated treatment of future clinical data by the FDA, the EMA or other regulatory authorities, including whether such data will be sufficient for approval; the success of future development activities for its product candidates; potential indications for which product candidates may be developed; the ability of Revelation to maintain the listing of its securities on NASDAQ; the expected duration over which Revelation's balances will fund its operations; and other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the SEC by Revelation.

Company Contact

Mike Porter
Investor Relations
Porter LaVay & Rose Inc.
Email: mike@plrinvest.com

Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: czygmont@revbiosciences.com

SOURCE: Revelation Biosciences, Inc.

View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Revelation Biosciences (REVB) announce on January 7, 2026 about GEMINI?

Revelation announced the start of GMP manufacturing for GEMINI and matching placebo to supply later‑stage clinical studies.

How does the GEMINI GMP run affect REVB's clinical plans?

The manufacturing run will provide clinical drug supply and enable randomized double‑blind, placebo‑controlled trials for later‑stage studies.

Did REVB meet with the FDA about GEMINI and when?

Yes; Revelation met with the FDA in December 2025 to seek feedback on the clinical development and regulatory pathway for GEMINI in AKI.

Is Revelation working with an external manufacturer for GEMINI (REVB)?

Yes; the company said it is working with a leading global contract manufacturing organization for the GMP run.

Are the FDA meeting minutes for REVB's December 2025 meeting available?

No; Revelation is currently awaiting the official FDA meeting minutes.